All In MedTech

Device Trial Radar · NCT01173965

Endometrial Ablation With Non-hysteroscopic Methods

Treatment of Dysfunctional Uterine Bleeding With Second Generation Ablation Devices: Microwaves (MEA®) vs Bipolar Impedance Control System (Novasure®)

Last checked: Nov 20, 2026Latest source record: Jul 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Jan 2008

Primary completion

Feb 2010

Study completion Feb 2011

Sponsor

Lead sponsor
Aristotle University Of ThessalonikiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 3, 2010

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 30 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Endometrial ablation in women with dysfunctional uterine bleeding using second generation ablation devices is a common widespread therapeutic approach. This study aims to prove that amenorrhoea rates using Novasure are higher than those observed in microwave endometrial ablation, one year following intervention.

Conditions

  • Dysfunctional Uterine Bleeding

Interventions

  • MEADevice

    Microwave endometrial ablation device

  • NovasureDevice

    Bipolar impedence control system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amenorrhoea rates one year after intervention

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • First Dept. Of ObGyn, Medical School Aristotle University of Thessaloniki, Papageorgiou Hospital

    Thessaloniki, Thessaloniki, Greece

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.